I'm not doubting it's approved or it's effectiveness as a product.
What I'm saying is if the product was going to be a success it would be a lot further along than it is now.
The ASX is littered with Australian companies with 'great products' that just don't translate into overseas sales for one reason or another.
In particular the US market that is completely controlled by big pharma, small companies never win in the US. Another example is ASX:NXS.
MVP's mngt should have just sold out to a big pharma company or to PE with a licencing deal with big pharma, that would have delivered the greatest shareholder return IMO.
Not to try & go overseas themselves.
Ann: Appendix 4C & Quarterly Activity Report - 31 March 2024, page-39
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.69M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 46.0¢ | 44.0¢ | $10.2K | 22.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41949 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 13548 | 3 |
View Market Depth
| Last trade - 15.47pm 04/10/2024 (20 minute delay) ? |
| MVP (ASX) Chart |